From the Department of Diagnostic Imaging (D.M.-M., S.L., C.R.).
Division of Neuro-oncology (M.Z., V.R.).
AJNR Am J Neuroradiol. 2018 May;39(5):949-955. doi: 10.3174/ajnr.A5578. Epub 2018 Mar 15.
Molecular grouping of medulloblastoma correlates with prognosis and supports the therapeutic strategy. We provide our experience with the imaging features of primary and metastatic disease in relation to the molecular groups.
One hundred nineteen consecutive patients (mean age, 7.3 ± 3.8 years at diagnosis; male, 79 [66.4%]) with a confirmed diagnosis of medulloblastoma and interpretable pretreatment MRIs were retrieved from our data base from January 2000 to December 2016. Each patient was assigned to group 3, or group 4 molecular groups. Then, we determined the imaging features of both primary and metastatic/recurrent disease predictive of molecular groups.
In addition to recently reported predictors based on primary tumor, including cerebellar peripheral location for (adjusted odds ratio = 9, < .0001), minimal enhancement of primary group 4 tumor (adjusted odds ratio = 5.2, < .0001), and cerebellopontine angle location for (adjusted odds ratio = 1.4, = .03), ependymal metastasis with diffusion restriction and minimal postcontrast enhancement ("mismatching pattern") (adjusted odds ratio = 2.8, = .001) for group 4 and spinal metastasis for group 3 (adjusted odds ratio = 1.9, = .01) also emerged as independent predictors of medulloblastoma molecular groups. Specifically, the presence of a metastasis in the third ventricular infundibular recess showing a mismatching pattern was significantly associated with group 4 ( = .02).
In addition to imaging features of primary tumors, some imaging patterns of metastatic dissemination in medulloblastoma seem characteristic, perhaps even specific to certain groups. This finding could further help in differentiating molecular groups, specifically groups 3 and 4, when the characteristics of the primary tumor overlap.
髓母细胞瘤的分子分组与预后相关,并支持治疗策略。我们提供了与分子组相关的原发性和转移性疾病的影像学特征的经验。
从 2000 年 1 月至 2016 年 12 月,我们从数据库中检索了 119 例连续患者(诊断时的平均年龄为 7.3±3.8 岁,男性 79 例[66.4%]),这些患者均经证实患有髓母细胞瘤,且预处理 MRI 可解读。将每个患者分配到 3 组或 4 组分子组。然后,我们确定了预测分子组的原发性和转移性/复发性疾病的影像学特征。
除了最近基于原发性肿瘤报道的预测因素,包括小脑外周位置为 (调整后的优势比=9, <.0001)、原发性 4 组肿瘤最小强化(调整后的优势比=5.2, <.0001)、桥小脑角位置为 (调整后的优势比=1.4,=.03),4 组的室管膜转移伴弥散受限和最小的对比后强化(“不匹配模式”)(调整后的优势比=2.8,=.001)和 3 组的脊髓转移(调整后的优势比=1.9,=.01)也成为髓母细胞瘤分子组的独立预测因素。具体来说,在第三脑室漏斗部出现不匹配模式的转移灶与 4 组显著相关(=.02)。
除了原发性肿瘤的影像学特征外,髓母细胞瘤转移扩散的一些影像学模式似乎具有特征性,甚至可能是特定于某些组的。当原发性肿瘤的特征重叠时,这一发现可能有助于进一步区分分子组,特别是 3 组和 4 组。